- 민트 벤처파트너스는
- 민트 벤처 파트너스는 바이오 헬스케어의 기술 사업화, 스타트업 창업, 스타트업 투자를 글로벌 파트너와 함께 합니다
News
- [Senda Biosciences] Closing of $98 Million Series
- 2021-06-11 hit.1,073
CAMBRIDGE, Mass., June 10, 2021 /PRNewswire/ -- Senda Biosciences, a company that is systematically harnessing the powerful molecular interactions that have evolved over millennia between humans, plants, and bacteria to develop new types of medicines, announced today the completion of a $55 million Series B extension financing, bringing its total Series B funding to $98 million and total funding raised to date to $143 million. Proceeds from the financing will be used to advance the development of Senda's platform and its therapeutic programs into clinical trials. Flagship Pioneering, Senda's founder, participated along with new investors including Longevity Vision Fund, Terra Magnum Capital Partners, Mayo Clinic, Partners Investment and Mint Venture Partners. Current investors Alexandria Venture Investments and State of Michigan Retirement System also participated.
"Senda's unique approach to
understanding and harnessing the interspecies interactions within each of us as
a means to treat and prevent human disease opens up tremendous new
opportunities for improving human health," said Guillaume Pfefer, Ph.D.,
Chief Executive Officer of Senda Biosciences and Partner at Flagship
Pioneering. "The Senda team has made great progress since launching in
late 2020. We have significantly advanced our platform and therapeutic
programs, established a strategic partnership with Nestlé Health Science, and
began to build a world-class team. Now we have closed a Series B extension
financing that will enable us to initiate multiple clinical programs as we
continue to build out our platform and pipeline. We're thrilled to have such a dedicated
group of investors backing our work and sharing our vision. We look forward to
sharing further updates on the progress of our lead programs as we move towards
our first clinical trials in early 2022."
"Humans have coevolved over millennia
with other species in order to survive, resulting in sophisticated mechanisms
that enable the exchange of molecular and genetic information between species
within us," said Scott Plevy, M.D., Chief Scientific Officer of Senda
Biosciences. "These interactions are as impactful to human health as our
genetics. Senda has generated significant data showing these interspecies
connections can be leveraged broadly to treat and prevent disease. To date, we
have produced proof-of-platform data showing the ability of our plant-derived
transfer systems to deliver large biomolecules such as mRNA and peptides, with
never-before-seen patterns of biodistribution. We've also generated preclinical
data showing we can engineer bacteria-derived therapeutics that enable tunable,
antigen-specific antibody and T cell responses. Finally, we've demonstrated the
ability to precisely intervene in bacteria-to-human pathways linked to a
variety of diseases."
About Senda Biosciences
Senda is systematically harnessing the
powerful molecular interactions that have evolved over millennia between
humans, plants, and bacteria to develop new types of medicines. Senda's
platform enables the deployment of proteins or genetic material throughout the
body in unprecedented ways, tunable modulation of the immune system, and
precise intervention at the point of interaction between human and non-human
species. By pioneering this new approach, called intersystems biology, the
company aims to develop novel medicines with unprecedented safety, efficacy,
and precision. To learn more, please visit the company's website at
www.sendabiosciences.com.
About Flagship Pioneering
Flagship Pioneering conceives, creates,
resources, and develops first-in-category life science platform companies to
transform human health and sustainability. Since its launch in 2000, the firm
has, through its Flagship Labs unit, applied its unique hypothesis-driven
innovation process to originate and foster more than 100 scientific ventures,
resulting in over $90 billion in aggregate value. To date, Flagship has
deployed over $2.4 billion in capital toward the founding and growth of its
pioneering companies alongside more than $19 billion of follow-on investments
from other institutions. The current Flagship ecosystem comprises 41 transformative
companies, including Axcella Health (NASDAQ: AXLA), Codiak BioSciences (NASDAQ:
CDAK) Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO),
Foghorn Therapeutics (NASDAQ: FHTX), Indigo Ag, Kaleido Biosciences (NASDAQ:
KLDO), Moderna (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Sana
Biotechnology (NASDAQ: SANA), Seres Therapeutics (NASDAQ: MCRB), and Sigilon
Therapeutics (NASDAQ: SGTX).
Contact
press@sendabiosciences.com
SOURCE Senda Biosciences
다음글
이전글